MW 370.5 Da, Purity >98%. Selective, active site directed, irreversible cPLA 2 and iPLA2 inhibitor. Potent FAAH inhibitor (IC50 = 2.5 nM). I nhibits A23187 (ab120287, ab142245, ab142244)-induced arachidonic acid release from platelets (IC50 = 600 nM). Potent, irreversible anandamide amidase inhibitor. Prolongs and intensifies aerobic exercise-induced antinociceptive effects *in vivo*.
Anandamide amidohydrolase, Anandamide amidohydrolase 1, CANN6, CB-R, CB1, CB1A, CB1K5, CB1R, CNR, CNR1_HUMAN, CPLA 2, Calcium dependent phospholipid binding protein, Cannabinoid receptor 1, Central cannabinoid receptor, Cytosolic phospholipase A2, Cytosolic phospholipase A2 group IVA, EC 3.1.1.23, FA2H, FAAH, FAAH1_HUMAN, Fatty acid 2-hydroxylase, Fatty acid alpha-hydroxylase, Fatty acid amide hydrolase, Fatty-acid amide hydrolase 1, HU-K5, Intracellular platelet activating factor acetylhydrolase alpha 2 subunit, Lysophospholipase, Lysophospholipase homolog, Lysophospholipase-like, MAGL, MGC102823, MGC126350, MGC138146, MGL, MGLL_HUMAN, Monoacylglycerol lipase, Monoglyceride lipase, OTTHUMP00000016838, OTTHUMP00000214579, Oleamide hydrolase, Oleamide hydrolase 1, PA1B2_HUMAN, PA24A_HUMAN, PAF AH beta subunit, PAF acetylhydrolase 30 kDa subunit, PAF-AH 30 kDa subunit, PAF-AH subunit beta, PAFAH1B2 protein, PAFAHB, PLA2G4, Phosphatidylcholine 2-acylhydrolase, Phospholipase A2, Phospholipase A2 group 4 A, Phospholipase A2 group IVA, Phospholipase A2, group IVA (cytosolic, calcium-dependent), Platelet activating factor acetylhydrolase 1b catalytic subunit 2, Platelet activating factor acetylhydrolase IB beta subunit, Platelet activating factor acetylhydrolase isoform Ib beta subunit, Platelet activating factor acetylhydrolase isoform Ib subunit 2, Platelet-activating factor acetylhydrolase IB subunit beta, cPLA2-alpha, pla2g4a
MW 370.5 Da, Purity >98%. Selective, active site directed, irreversible cPLA 2 and iPLA2 inhibitor. Potent FAAH inhibitor (IC50 = 2.5 nM). I nhibits A23187 (ab120287, ab142245, ab142244)-induced arachidonic acid release from platelets (IC50 = 600 nM). Potent, irreversible anandamide amidase inhibitor. Prolongs and intensifies aerobic exercise-induced antinociceptive effects *in vivo*.
Selective, active site directed, irreversible cPLA 2 and iPLA2 inhibitor. Potent FAAH inhibitor (IC50 = 2.5 nM). I nhibits A23187 (ab120287, ab142245, ab142244)-induced arachidonic acid release from platelets (IC50 = 600 nM). Potent, irreversible anandamide amidase inhibitor. Prolongs and intensifies aerobic exercise-induced antinociceptive effects *in vivo*.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2D chemical structure image of ab141763, Methyl Arachidonyl Fluorophosphonate,irreversible cPLA2 and iPLA2 inhibitor
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com